QIAGEN today announced the results of a study evaluating the accuracy of the QIAGEN Clinical Insight (QCI) solution by Counsyl, a genetic screening and genetic counseling company.
Evaluation of clinical variant interpretation platform presented by Counsyl at ASHG 2017 |
| [19-October-2017] |
| ORLANDO, GERMANTOWN, Maryland, and HILDEN, Germany, October 19, 2017 /PRNewswire/ --
QIAGEN today announced the results of a study evaluating the accuracy of the QIAGEN Clinical Insight (QCI) solution by Counsyl, a genetic screening and genetic counseling company. In an evaluation, Counsyl - an early QCI adopter - found that it reduced the time required to search for literature references to interpret and score variants by 75 percent while maintaining accuracy. As a result, Counsyl has implemented QCI as an integral part of its literature search process to increase productivity and scalability. Results of the evaluation are presented today in a poster at the American Society of Human Genetics (ASHG). Click here [https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-19-Counsyl-ASHG?sc_lang=en ] for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-19-Counsyl-ASHG?sc_lang=en Contacts: Investor Relations John Gilardi E-Mail: ir@QIAGEN.com +49-2103-29-11711 Public Relations Dr. Thomas Theuringer E-Mail: pr@QIAGEN.com +49-2103-29-11826
SOURCE QIAGEN | ||
Company Codes: Frankfurt:QIA, NASDAQ-NMS:QGEN, Bloomberg:QGEN@US, Bloomberg:QIA@GR, RICS:QGEN.F, ISIN:NL0000240000 |
